MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$27,154K
Free Cash flow
-$52,680K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Loss on lease termination
Collaboration revenue
Others
Negative Cash Flow Breakdown
Operating lease liabilities
Personnel-related
Loss on lease termination
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Collaboration revenue
11,082
-
Personnel-related
30,342
-
Preclinical and manufacturing
12,910
-
Facilities-related
16,392
-
Stock-based compensation
5,681
-
Lab supplies
2,802
-
Consulting and professional services
9,872
-
Loss on lease termination
23,838
-
Other
3,151
-
Total operating expenses
57,312
-
Loss from operations
-46,230
-
Other income and interest income, net
4,985
-
Net loss
-5,520
-35,725
Loss on lease termination
25,490
-1,652
Stock-based compensation expense
1,977
3,704
Other
-
-139
Depreciation and amortization expense
1,404
2,270
Accretion of discount on marketable securities, net
696
1,881
Losses on property and equipment, net
-1,911
-
Collaboration receivable
135
-968
Prepaid expenses and other current assets
-1,182
-2,732
Operating lease right-of-use assets
-986
-1,895
Other noncurrent assets
-67
-472
Accounts payable
-168
893
Accrued expenses and other current liabilities
6,658
-3,457
Deferred revenue
-1,202
-7,840
Other noncurrent liabilities
0
-223
Operating lease liabilities
-33,793
-10,509
Net cash used in operating activities
-52,680
-45,188
Purchases of property and equipment
0
705
Proceeds from sale of property and equipment
241
234
Purchases of marketable securities
14,713
51,621
Maturities of marketable securities
40,000
70,000
Net cash provided by (used in) investing activities
25,528
17,908
Proceeds from exercise of stock options and espp, net
0
81
Tax withholding payments related to net share settlements of restricted stock units
2
8
Net cash used in financing activities
-2
73
Net decrease in cash, cash equivalents and restricted cash
-27,154
-27,207
Cash and cash equivalents at beginning of period
78,453
-
Cash and cash equivalents at end of period
24,092
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$40,000K
Proceeds from sale of
property and equipment
$241K
Net cash provided by
(used in) investing...
$25,528K
Canceled cashflow
$14,713K
Net decrease in
cash, cash...
-$27,154K
Canceled cashflow
$25,528K
Accrued expenses and
other current...
$6,658K
Stock-based compensation
expense
$1,977K
Losses on property and
equipment, net
-$1,911K
Depreciation and
amortization expense
$1,404K
Prepaid expenses and
other current assets
-$1,182K
Operating lease
right-of-use assets
-$986K
Other noncurrent
assets
-$67K
Purchases of marketable
securities
$14,713K
Net cash used in
operating activities
-$52,680K
Canceled cashflow
$14,185K
Net cash used in
financing activities
-$2K
something is missing
$35,725K
Other income and
interest income, net
$4,985K
Operating lease
liabilities
-$33,793K
Loss on lease
termination
$25,490K
Net loss
-$5,520K
Deferred revenue
-$1,202K
Accretion of discount on
marketable securities, net
$696K
Accounts payable
-$168K
Tax withholding
payments related to net...
$2K
Canceled cashflow
$40,710K
Collaboration revenue
$11,082K
Loss from operations
-$46,230K
Canceled cashflow
$11,082K
Loss on lease
termination
$23,838K
Total operating
expenses
$57,312K
Canceled cashflow
$23,838K
Personnel-related
$30,342K
Facilities-related
$16,392K
Preclinical and
manufacturing
$12,910K
Consulting and
professional services
$9,872K
Stock-based compensation
$5,681K
Other
$3,151K
Lab supplies
$2,802K
Buy us a coffee
Generation Bio Co. (GBIO)
Generation Bio Co. (GBIO)